• Sleep · Nov 2011

    Clinical Trial

    Treating obstructive sleep apnea with hypoglossal nerve stimulation.

    • Peter R Eastwood, Maree Barnes, Jennifer H Walsh, Kathleen J Maddison, Geoffrey Hee, Alan R Schwartz, Philip L Smith, Atul Malhotra, R Douglas McEvoy, John R Wheatley, Fergal J O'Donoghue, Peter D Rochford, Tom Churchward, Matthew C Campbell, Carsten E Palme, Sam Robinson, George S Goding, Danny J Eckert, Amy S Jordan, Peter G Catcheside, Louise Tyler, Nick A Antic, Christopher J Worsnop, Eric J Kezirian, and David R Hillman.
    • Sir Charles Gairdner Hospital, Perth, Australia. Peter.Eastwood@health.wa.gov.au
    • Sleep. 2011 Nov 1;34(11):1479-86.

    BackgroundReduced upper airway muscle activity during sleep is fundamental to obstructive sleep apnea (OSA) pathogenesis. Hypoglossal nerve stimulation (HGNS) counteracts this problem, with potential to reduce OSA severity.Study ObjectivesTo examine safety and efficacy of a novel HGNS system (HGNS, Apnex Medical, Inc.) in treating OSA.ParticipantsTwenty-one patients, 67% male, age (mean ± SD) 53.6 ± 9.2 years, with moderate to severe OSA and unable to tolerate continuous positive airway pressure (CPAP).DesignEach participant underwent surgical implantation of the HGNS system in a prospective single-arm interventional trial. OSA severity was defined by apnea-hypopnea index (AHI) during in-laboratory polysomnography (PSG) at baseline and 3 and 6 months post-implant. Therapy compliance was assessed by nightly hours of use. Symptoms were assessed using the Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), Calgary Sleep Apnea Quality of Life Index (SAQLI), and the Beck Depression Inventory (BDI).ResultsHGNS was used on 89% ± 15% of nights (n = 21). On these nights, it was used for 5.8 ± 1.6 h per night. Nineteen of 21 participants had baseline and 6-month PSGs. There was a significant improvement (all P < 0.05) from baseline to 6 months in: AHI (43.1 ± 17.5 to 19.5 ± 16.7), ESS (12.1 ± 4.7 to 8.1 ± 4.4), FOSQ (14.4 ± 2.0 to 16.7 ± 2.2), SAQLI (3.2 ± 1.0 to 4.9 ± 1.3), and BDI (15.8 ± 9.0 to 9.7 ± 7.6). Two serious device-related adverse events occurred: an infection requiring device removal and a stimulation lead cuff dislodgement requiring replacement.ConclusionsHGNS demonstrated favorable safety, efficacy, and compliance. Participants experienced a significant decrease in OSA severity and OSA-associated symptoms.Clinical Trial InformationNAME: Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea.Registration NumberNCT01186926. URL: http://clinicaltrials.gov/ct2/show/NCT01186926.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…